Ketorolac Dosing for Postoperative Pain
For postoperative pain in adults, administer ketorolac 30 mg IV every 6 hours (maximum 120 mg/day) for patients under 65 years, and reduce to 15 mg IV every 6 hours (maximum 60 mg/day) for patients ≥65 years, those with renal impairment, or body weight <50 kg, with treatment duration not exceeding 5 days. 1
Standard Dosing Regimen
Patients <65 Years (Normal Renal Function, ≥50 kg)
Multiple-dose regimen:
- 30 mg IV every 6 hours
- Maximum daily dose: 120 mg
- IV bolus must be given over ≥15 seconds 1
Single-dose option:
- 30 mg IV (single administration only) 1
Patients ≥65 Years, Renal Impairment, or <50 kg
Multiple-dose regimen:
- 15 mg IV every 6 hours
- Maximum daily dose: 60 mg 1
Single-dose option:
- 15 mg IV (single administration only) 1
Critical Duration Limitation
Maximum treatment duration: 5 days for all patients, regardless of route or formulation 1. This strict limitation exists because:
- Risk of serious gastrointestinal bleeding increases with duration
- Renal toxicity risk accumulates over time
- Cardiovascular thrombotic events may increase with prolonged use 1
Renal Impairment Considerations
Ketorolac is contraindicated in advanced renal impairment 1. For patients with moderate renal impairment (CrCl 30-59 mL/min):
- Use the reduced dose of 15 mg IV every 6 hours (maximum 60 mg/day) 1
- Monitor urine output and renal function parameters closely 2
- Avoid in patients with CrCl <30 mL/min 1
The concern stems from ketorolac's mechanism of inhibiting renal prostaglandin synthesis, which can precipitate acute renal failure, particularly in volume-depleted postoperative patients 2. Correct hypovolemia before administering ketorolac 1.
Efficacy Evidence
The 30 mg dose demonstrates robust analgesic efficacy. Meta-analysis data shows:
- Clinically meaningful pain reduction at 0-6 hours post-dose (VAS reduction of 1.42 points, exceeding the minimal clinically important difference) 3
- Significant opioid-sparing effect with mean reduction of 1.64 mg IV morphine equivalents 4
- Reduction in postoperative nausea and vomiting (odds ratio 0.49) with the 60 mg dose 4
However, a non-inferiority trial comparing 15 mg versus 30 mg failed to demonstrate that 15 mg was non-inferior for spine surgery, though the difference was not statistically significant 5. This suggests the 30 mg dose is preferable when not contraindicated by age, weight, or renal function.
Safety Profile and Contraindications
Absolute contraindications 1:
- Active peptic ulcer disease or GI bleeding
- Advanced renal impairment (CrCl <30 mL/min)
- Suspected cerebrovascular bleeding or hemorrhagic diathesis
- Coronary artery bypass graft surgery setting
- Hypersensitivity to NSAIDs or aspirin
- Labor and delivery
- Concomitant use with other NSAIDs or aspirin
Common pitfalls to avoid:
- Do not exceed 5-day duration under any circumstances
- Do not increase dose or frequency for breakthrough pain; instead add low-dose opioids 1
- Do not mix in syringe with morphine, meperidine, promethazine, or hydroxyzine (causes precipitation) 1
- Elderly patients require dose reduction even with normal creatinine due to age-related physiologic changes 6
Multimodal Analgesia Context
Ketorolac functions optimally as part of a multimodal analgesic strategy 6. The ASA guidelines emphasize that perioperative pain management should integrate multiple modalities rather than relying on single agents 6. For breakthrough pain, supplement with low-dose opioids rather than escalating ketorolac dose 1.
Monitoring Requirements
- Vigilant dose titration in elderly patients to balance efficacy against adverse effects like somnolence 6
- Close attention to urine output and renal function parameters, especially in postoperative patients with third-spacing 2
- Monitor for signs of GI bleeding, which can occur without warning 1
The evidence supports ketorolac as an effective postoperative analgesic when dosed appropriately with strict attention to patient-specific factors and duration limits.